EMJ Hematology 9 [Supplement 6] . 2021

In this issue

APPROXIMATELY 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapsed/refractory forms of the disease (R/R DLBCL). With effective forms of treatment currently lacking, there is an increasing need for the development of novel therapies to successfully treat the disease. This review provides a summary of the research presented by a panel of three experts at the virtual webcast symposium conference hosted by PeerVoice on 20th May 2021.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given